Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3075836rdf:typepubmed:Citationlld:pubmed
pubmed-article:3075836lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:3075836lifeskim:mentionsumls-concept:C0086409lld:lifeskim
pubmed-article:3075836lifeskim:mentionsumls-concept:C0282116lld:lifeskim
pubmed-article:3075836lifeskim:mentionsumls-concept:C0206012lld:lifeskim
pubmed-article:3075836lifeskim:mentionsumls-concept:C0376560lld:lifeskim
pubmed-article:3075836pubmed:dateCreated1989-8-14lld:pubmed
pubmed-article:3075836pubmed:abstractTextA total of 42 patients (22 previously untreated and 20 previously treated) with GH deficiency were included in a Spanish multicentre trial of recombinant somatropin, 0.5 IU/kg/week. In previously untreated patients typical catch-up growth was observed and the height velocity increased from 3.3 +/- 0.6 cm/year to 9.8 +/- 2.4 cm/year during 1 year of therapy. In previously treated children, the height velocity was maintained (7.2 +/- 2.0 cm/year at the start and 7.9 +/- 1.6 cm/year after 1 year). No anti-GH antibodies were detected in previously untreated patients, and they disappeared from previously treated ones. No adverse reactions were reported.lld:pubmed
pubmed-article:3075836pubmed:languageenglld:pubmed
pubmed-article:3075836pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3075836pubmed:citationSubsetIMlld:pubmed
pubmed-article:3075836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3075836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3075836pubmed:statusMEDLINElld:pubmed
pubmed-article:3075836pubmed:issn0300-8843lld:pubmed
pubmed-article:3075836pubmed:authorpubmed-author:Vicens-Calvet...lld:pubmed
pubmed-article:3075836pubmed:authorpubmed-author:Cuatrecasas-M...lld:pubmed
pubmed-article:3075836pubmed:issnTypePrintlld:pubmed
pubmed-article:3075836pubmed:volume347lld:pubmed
pubmed-article:3075836pubmed:ownerNLMlld:pubmed
pubmed-article:3075836pubmed:authorsCompleteYlld:pubmed
pubmed-article:3075836pubmed:pagination180-3lld:pubmed
pubmed-article:3075836pubmed:dateRevised2008-2-20lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:meshHeadingpubmed-meshheading:3075836-...lld:pubmed
pubmed-article:3075836pubmed:year1988lld:pubmed
pubmed-article:3075836pubmed:articleTitleSpanish multicentre trial of recombinant somatropin. Spanish Collaborative Group.lld:pubmed
pubmed-article:3075836pubmed:affiliationEndocrinology Unit, Children's Hospital Vall d'Hebron, Barcelona, Spain.lld:pubmed
pubmed-article:3075836pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3075836pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3075836pubmed:publicationTypeMulticenter Studylld:pubmed